| Literature DB >> 31881974 |
Zhangjian Chen1,2, Di Zhou1,2, Shuo Han1,2, Shupei Zhou3, Guang Jia4,5.
Abstract
BACKGROUND: Due to its excellent physicochemical properEntities:
Keywords: Gut microbiota; Gut-liver axis; Hepatotoxicity; Nanomaterials; Titanium dioxide
Mesh:
Substances:
Year: 2019 PMID: 31881974 PMCID: PMC6935065 DOI: 10.1186/s12989-019-0332-2
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Characterization of TiO2 NPs. a The representative SEM image of TiO2 NPs. b The determination of element content of TiO2 NPs by EDX analysis. c Size distribution and average size of TiO2 NPs measured from SEM images. d The crystal analysis chart for TiO2 NPs by XRD. The hydrodynamic diameter (e) and zeta potential (f) of TiO2 NPs (1 mg/mL) in ultrapure water (H2O), artificial gastric juice (AGJ), and artificial intestinal juice (AIJ). Significant difference compared with the group of TiO2 NPs in H2O (∗p < 0.05). PDI: poly dispersity index
Fig. 2Hepatotoxicity induced by TiO2 NPs via oral exposure for 90 days. a Schematic diagram for oral administration of TiO2 NPs (0, 2, 10, and 50 mg/kg/d) in SD rats for 90 d. Hepatotoxicity was evaluated by serum biochemical indicators related to liver damage and histopathological observation. The serum levels of TBIL (b), TP (c), ALB (d), GLB (e), ALT (F), and AST (g) in rats were detected after TiO2 NPs treatment for 90 consecutive days. h and i were representative pathological images of HE staining under light microscopy (magnification: 20×). Fatty degeneration of hepatocytes, which appeared as fat vacuoles (black arrow), was evident in the 50 mg/kg BW TiO2 NPs treated group. j and k were representative TEM images of liver tissues (magnification: 8000×). Under TEM, it was observed that vacuolation of mitochondria (yellow arrows) around nuclei (red arrow) in hepatocytes was obvious in the 50 mg/kg BW TiO2 NPs treated group. Significant difference compared with the control group (∗ p < 0.05). TBIL: total bilirubin, TP: total protein, ALB: albumin, GLB: globulin, ALT: alanine aminotransferase, AST: aspartate aminotransferase
Fig. 3Effect of TiO2 NPs on liver metabolism analyzed by non-targeted metabonomics using HPLC-MS. a Heatmap of metabolite concentrations, which shows the different metabolites in liver tissues of rats in the control group and high-dose TiO2 NPs (50 mg/kg) treated group. Each row represents a metabolite, and each column represents a sample. The color of each grid represents the relative concentration of the metabolites in the corresponding sample. b PCA and OPLS-DA scoring maps of metabolites in the control and TiO2 NPs treated group as well as quality control (Qc) samples. c Z Score Map of differential metabolites between the liver samples in the control and TiO2 NPs treated group. Z score = (the sample concentration - average concentration of samples in the control group)/ standard deviation of sample concentrations in the control group. Each point represents a sample, blue as the control group and red as the treat group. d KEGG pathway analysis of differential metabolites. X-axis represents the Pathway Impact obtained by the out-degree centrality algorithm. The size of the point is related to the Pathway Impact. Y-axis represents the negative logarithm of the p value (−log(p)) obtained by the pathway enrichment analysis. The yellow-red color change of the point is positively related to the -log(p). The names of pathways are labeled in the graph with -log(p) > 2 or Pathway Impact > 0.1
Effect of TiO2 NPs on oxidative stress biomarkers in the liver tissue and inflammatory cytokines in serum of rats after oral exposure for 90 days
| Control | TiO2 NPs treated doses (mg/kg BW) | |||
|---|---|---|---|---|
| 2 | 10 | 50 | ||
| GSH (nmol/mg protein) | 19.81 ± 4.60 | 21.20 ± 5.62 | 18.51 ± 3.80* | 17.28 ± 3.48* |
| GSSG (nmol/mg protein) | 8.82 ± 1.27 | 9.69 ± 1.53 | 9.45 ± 1.31* | 9.28 ± 2.13* |
| GSH/GSSG | 2.23 ± 0.23 | 2.18 ± 0.44 | 1.95 ± 0.22* | 1.88 ± 0.23* |
| GSH-Px (mU/mg protein) | 161.18 ± 11.43 | 192.84 ± 57.97 | 205.05 ± 40.47* | 210.04 ± 82.34* |
| MDA (nmol/mg protein) | 3.40 ± 2.21 | 3.02 ± 2.49 | 11.82 ± 17.49 | 43.80 ± 27.51* |
| SOD (U/mg protein) | 10.56 ± 1.06 | 12.62 ± 4.76 | 13.64 ± 2.93* | 14.84 ± 6.30 |
| IL-1α (pg/mL) | 11.48 ± 2.34 | 10.35 ± 0.64 | 11.40 ± 1.23 | 13.41 ± 2.54* |
| IL-4 (pg/mL) | 1.35 ± 0.11 | 1.40 ± 0.18 | 1.42 ± 0.13 | 1.83 ± 1.38* |
| TNF (pg/mL) | 13.69 ± 1.57 | 13.43 ± 2.80 | 14.36 ± 2.30 | 13.51 ± 1.43* |
* Significant difference compared to the control group (p < 0.05). NPs nanoparticles, BW body weight, GSH reduced glutathione, GSH-Px glutathione peroxidase, GSSG oxidized glutathione, MDA malondialdehyde, lipid peroxidation products, SOD superoxide dismutase, IL interleukin, TNF tumor necrosis factor
Fig. 4Effect of TiO2 NPs on gut microbiota after oral administration for 90 days. a Top four relative abundance of bacteria at phylum-level. b Ratio of relative abundance between Firmicutes and Bacteroidetes, which may be closely related to adverse health effects of hosts. Comparison of Alpha Diversity of gut microbiota between different groups using Chao1 (c), ACE (d), and PD_Whole_Tree (e). f Comparison of Beta Diversity of gut microbiota between different groups using non-linear model NMDS method based on OTUs information in samples. * represents statistical difference (p < 0.05)
Fig. 5Differential gut microbiota between the samples in the control and TiO2 NPs treated group. a Evolutionary branch diagram of differential gut microbiota. The circle radiated from inside to outside represents the classification level from phylum to species. Each small circle at different classification levels represents a kind of bacteria at the corresponding level. The diameter of the small circle is positively related to the relative abundance. Coloring principle: bacteria with no significant difference between groups colored by yellow; bacteria with enrichment (LDA > 4) in the control group, medium and high dose of TiO2 NPs treated group colored by red, green, and blue, respectively. The relative abundance of Lactobacillus_reuteri (b) and Romboutsia (c) were significantly changed in the TiO2 NPs treated group, compared with the control group. * represents statistical difference (p < 0.05)
Fig. 6Effect of TiO2 NPs on the content of LPS and SCFAs. a LPS concentrations in the serum and fecal samples increased significantly in the TiO2 NPs exposure groups compared with the control group. b SCFAs, including acetic acid (AA), propionic acid (PA), isobutyric acid (IBA), butyric acid (BA), isovaleric acid (IVA), and hexanoic acid (HA), did not change significantly after exposure to TiO2 NPs in the feces. Significant difference compared with the control group (∗ p < 0.05). LPS: lipopolysaccharides; SCFAs: short-chain fatty acids
Fig. 7Interaction network of gut microbiota, liver metabolism, and hepatotoxicity after oral administration of TiO2 NPs. The changes of gut microbiota represented by increased L. reuteri and decreased Romboutsia led to the changes of intestinal metabolic function. The glycosaminoglycan degradation, fat digestion and absorption, and autoimmune-related metabolic pathways of gut microbiota increased significantly after exposure to TiO2 NPs. In addition, LPS produced by gut microbiota increased significantly, which may be a key factor in the subsequent liver effects. Hepatotoxicity manifested as changes in liver function and. Metabolic disorders and redox imbalances should be the main causes of liver function changes. In the complex metabolic network of the liver, glutamate, glutamine and glutathione may be the key metabolites leading the generation of energy-related metabolic disorders and imbalance of oxidation/antioxidation